Program
mavorixafor
Also written as “Mavorixafor”, “X4P-001” and “AMD11070”.
Its studies are mostly in Neutropenia · Carcinoma, Renal Cell · Hepatic Insufficiency · Waldenstrom Macroglobulinemia · Triple Negative Breast Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| X4 Pharmaceuticals | 122 open or running | phase 3since Jun 19, 2019 | Jan 20, 2016 | Sep 2027phase 3 · NCT06056297 |
| Abbisko Cayman | 10 open or running | phase 2since Sep 25, 2021 | Sep 25, 2021 | none ahead |
| Sanofi | 10 open or running | phase 1since Aug 3, 2006 | Aug 3, 2006 | none ahead |
Also a collaborator on its studies: covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2006First study: phase 1 study in HIV InfectionsNew to SanofiSanofi · NCT00361101 · 10 enrolled · United States, United Kingdom
- Jan 20, 2016X4 Pharmaceuticals's first study: phase 2 study in Carcinoma, Renal CellNew to X4 PharmaceuticalsX4 Pharmaceuticals · NCT02667886 · 74 enrolled · United States, Korea, Republic of
- Feb 4, 2016Phase 1 study in HealthyX4 Pharmaceuticals · NCT02680782 · 15 enrolled · United States
- Jul 1, 2016Phase 1 study in MelanomaX4 Pharmaceuticals · NCT02823405 · 16 enrolled · United States
- Sep 30, 2016Phase 2 study in Carcinoma, Renal CellX4 Pharmaceuticals · NCT02923531 · 9 enrolled · United States
- Dec 20, 2016Phase 2 study in WHIM syndromeX4 Pharmaceuticals · NCT03005327 · 8 enrolled · United States, Australia
- Jun 19, 2019Phase 3 study in WHIM syndromeX4 Pharmaceuticals · NCT03995108 · 31 enrolled · United States, Australia, Austria and more
- Nov 4, 2019Phase 2 study in NeutropeniaX4 Pharmaceuticals · NCT04154488 · 32 enrolled · United States
- Feb 12, 2020Phase 1 study in Waldenstrom MacroglobulinemiaX4 Pharmaceuticals · NCT04274738 · 16 enrolled · United States, Greece
- Sep 25, 2021Abbisko Cayman's first study: phase 2 study in Triple Negative Breast NeoplasmsNew to Abbisko CaymanAbbisko Cayman · NCT05103917 · 24 enrolled · China
- Sep 20, 2023Phase 3 study in NeutropeniaX4 Pharmaceuticals · NCT06056297 · 176 planned · United States, Argentina, Australia and more
- Feb 27, 20252 phase 1 studiesX4 Pharmaceuticals · NCT06914869, NCT06858696
- Oct 20, 2026Phase 2 study in Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersX4 Pharmaceuticals · NCT07902830 · 40 planned
Ahead
- Sep 2027Primary completion: phase 3 study in NeutropeniaX4 Pharmaceuticals · NCT06056297
- Jan 30, 2029Primary completion: phase 2 study in Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersX4 Pharmaceuticals · NCT07902830
TargetBeta
“An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), ”NCIt, by rule
“C-X-C chemokine receptor type 4 antagonist”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07902830Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders | 2 | Not yet recruiting | X4 Pharmaceuticals | Jan 30, 2029 | 40 |
| NCT06914869Healthy Participants · United States | 1 | Completed | X4 Pharmaceuticals | May 19, 2025 | 38 |
| NCT06858696Hepatic Insufficiency · United States | 1 | Completed | X4 Pharmaceuticals | Jan 12, 2026 | 39 |
| NCT06056297Neutropenia · United States, Argentina, Australia and more | 3 | Recruiting | X4 Pharmaceuticals | Sep 2027 | 176 |
| NCT05103917Triple Negative Breast Neoplasms · China | 2 | UNKNOWN | Abbisko Cayman | Nov 24, 2022 | 24 |
| NCT04274738Waldenstrom Macroglobulinemia · United States, Greece | 1 | Completed | X4 Pharmaceuticals | Oct 31, 2022 | 16 |
| NCT04154488Neutropenia · United States | 2 | Completed | X4 Pharmaceuticals | Aug 27, 2024 | 32 |
| NCT03995108WHIM syndrome · United States, Australia, Austria and more | 3 | Completed | X4 Pharmaceuticals | Dec 23, 2025 | 31 |
| NCT03005327WHIM syndrome · United States, Australia | 2 | Completed | X4 Pharmaceuticals | Jun 16, 2022 | 8 |
| NCT02923531Carcinoma, Renal Cell · United States | 2 | Terminated | X4 Pharmaceuticals | Aug 8, 2018 | 9 |
| NCT02823405Melanoma · United States | 1 | Completed | X4 Pharmaceuticals | Mar 15, 2018 | 16 |
| NCT02680782Healthy · United States | 1 | Terminated | X4 Pharmaceuticals | Feb 28, 2016 | 15 |
| NCT02667886Carcinoma, Renal Cell · United States, Korea, Republic of | 2 | Completed | X4 Pharmaceuticals | Apr 14, 2022 | 74 |
| NCT00361101HIV Infections · United States, United Kingdom | 1 | Completed | Sanofi | Aug 2006 | 10 |
How it is read
Names in the registry
- “Mavorixafor”, 7 entries
- “X4P-001”, 6 entries
- “AMD11070”, 1 entry
Conditions, from the studies’ own filings
- Neutropenia, 3 studies
- Carcinoma, Renal Cell, 2 studies
- Hepatic Insufficiency, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.